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1. Introduction
It hasbeen recognized more than one hundred yeas ago thatatmosphericoxygen, the breath
of life, apart frombeing beneficial, can be toxic to alllivig orgmisms.Today we know that in both, the
beneficial and the harrrful effects, the same types of reactive oxygen species (RO$) are
involved. It is fairto saythatthese spedes constitute some sort of chemical interface between life and
death.
In th is interface iron is a double-edged swol, as it may cause iron induced oxidative stress. In
moderate quantitiesand leashed to protein or other iron binding spedes, it is an essential element in all
cell metabolisms and growth, but toxic when unleashed. The unique abiities of iron to vary oxidation
state, redox potential, and electronic spin configuratbn in response to different ligand environments,
are important criteria enabling iron to play multifunctbnal roles as a protein cofactor. For exarrple, iron-
containing proteins play fundamental roles in respiration, oxygen delivery to tissues, DNA synthesis,
and regulation of the citc acid cycle. Concurrentwith the evolution of complex iron-containhg proteins,
nature needed to design an efficient and non toxic means of controlling iron absorption, transport, and
stooge. This is because the same physical properties that allow iron to act as an
efficient cofactor in controlled redox chemistry, also allow iron to act as a potent
toxin when not shielded from oxidatively susceptible biomolecules.
Toxicity’sand pathologies, associated with the oxidation of DNA, proteins, lipids, and carbohydrates are
subjects of intensive research. Collectively, the oxidation of these molecules has been termed
,,oxidative stress", which can be defhed as the oxidation of cellular components thereby
introducing harmto that cellor tissue.
The aimof this report is to defie the role of iron in oxidative stress by reviewing potential iron spedes,
mechanisms of actbn, and predinical and clinical situations, where oxidative stress is involved in
relationship to the iron status. It willbe shown how ROS are produced and which of reactions they can
inilate on the molecular level and also to what kind of effects (side effects) ROS can cause in biobgical
systems. A spedal focus is given to DNA damage and cardnogenesis, lipid peroxidation in pregnancy
and prematures, Fe+ -induced cytotoxicity and injuries to gastric cells, immunology, neu3toxicity, iron
overload, pro-oxidant effects of ascorbic acid, and erythropoietin activity. Mosly situations where iron
therapy is often indicated. Therefore also a critical evaluation of today’s used iron therapy willbe given.
2. Che mistry
By definition, reactive oxygen species (ROS) are the spedes that appear in the series of
four one-electron-uptake steps when an oxygen molecule, O=, is reduced to water, HO. In the
laboratoryexperimentthiscan be achieved by electrocherrical reduction ofO in the aqueous solution
of an inert electrolyte.
This lecture was presented at the European Cooperation in Scientific Research and Technology
(COST) andthe Chemistry ofMetals in Medicine (COIVM) mee#’ng in Louvaine-la-Neuve, Belgium 22.
25. January 1997.
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Figure 1 Theseries ofROSemetging fromthestepwise reduction ofOto HO. The dots in the two
spedes "0 and "OH indicate that they are radicals, L e. they contain an uneven tot number of
electrons. Thesymbol ofan electron is e.
Figure 2 shows how iron spedes can promote the formation of ROS by cherrical reactbns. This has
been verified in vitro as wellas in vivomodel systems such as cell cultures.
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The hydrated ferrous ion Fem+ and ferric hydroxide can interact
in processes that lead to the formation of both free and latent
hydroxyl radicals, "OH.
Figure 2: The hydrated ferrous ion Fe
/ andfertic hydroxide can interact in processes that lead to the
formation ofboth free and latent hydroxyl radicals "OH. The scheme is based on reaction (1), (2), and
(3). The surface co-ordinatbn of hydroperoxide HOE is the ini#al step in the wellknown disproportbna-
tion ofHO according to reaction (4), which is catlyzed by ferric hydroxides.
Fe(OHh + "O + 3H
/ Fe+ + O + 3 HO (1)
Fe
2+ + H202 + H+ "-- Fe(ll) + "OH + HO (2)
Fe+ + "OH + H+ Fe(ll) + HO (3)
HO +HO ; 2 H20 + O (4)
Physiologically, in living organisms, the first reaction in Fig. 2 is rather irrelevant, as them are no fluids
that contain an excess of ferrous ions, Fe/, in an oxygenated solution. A deliberately caused
exception to this situation results when ferrous salts are used in oral iron therapy.
The mucosal boundary is then exposed to gastric fluid with a fairly high concentratbn of ferrous ions,
which immediately form superoxide radicals when they encounter oxygen molecules. This
admhistration of iron(ll) preparations therefore involves an artificial poisoning by reactive oxygen
spedes, which is very simiar to poisoning by radiation from radbisotopes (GL)nther 1990). However,
manybiochemistsand phan’nacologists believe thatferrous salttherapy is quite harmless.
3. Biochemistry
Localized within the mitochondriaamthe enzymes of the citdc acid cycle, the electron transport
arrangements, which delivers the electrons abstracted from intermediates of the citric cycle to oxygen,
and the means by which the enecjy of this process is conserved by linking it to the formation of ATP.
The first electron-acceptorof the re spiratory chain is NADwhich is reduced to NAD. The two H’s,
respectively the electron pair, reduce in the following steps flavoproteh (FP), Ubichinon (Coenzym Q),
Cytochrom b + c, Cytochrom c and finally Cytochrom a + a. Cyto-chromoxidase and oxygen build HO
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with two H/. Thereby the energy is conserved in 3 moles ATP per mol HO. Each element of the
respiratorychain has itsown reduction potential, which allows a controlled reduction ofO to HO.
The concept of reduction potential is very useful in chemistry and biochemistry and is directly
connected with the free energy of a redox reaction. Thereby the free energy, E, is dependent o n
the stability of the oxidized and reduced species, and of the concentrations of
each reactant according to the following equation:
R T Coxiz E=E + n e F In Cre’c"’d
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Figure 3" The reduction potentials of varbus iron(lll)-oompounds at pH 7.0 are listed, as wellas the
correspondhg reactions, which can takeplace underphysiological conditions. Fontecave et al. (1993),
modtied by Geisser(1997).
4. Biological Observations
Living organisms have developed defense systems which prevent or correct
oxidative stress.
The primary defense system involves strict compartmentalization of molecules which are capable
of catalyzing reactions with molecular oxygen.
The second defense then, is provided by the dismutases, i.e. superoxide dismutases, which
convert =O toO andHO, while the latter is transformed by catalase backto the innocuous molecules
O, and HO.
However, there is alsoathird defense system, which is able to cope with HO and with the most
toxic hydroxyl radical OH. Thisthil system involves the intracellular removal of HO by glutathione in
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conjunction with glutathione peroxidase, and the extracellular removal of *O by ascorbate (vitamin C),
or o-tocopherol (vitamin E).
Oxidase
O , "O
Figure 4: Thesuperoxide ion is the source of the other reactive oxygen spedesHO and "OH. The
spedes, superoxide0 and hydrogen peroxide HO are removed by the enzymes superoxide
disntase (SOD) and catlase (CA 7), respective/. The oxidases and peroxidases use oxygen for
oxidative changes oforgmic substrates. Free0 appearas by-productsof oxidase activities. Themost
reactive spedes is the radical"OH.An important source of thisradbal is the Fenton reaction.
The amount of ROS present in the tissue is determined by the rate of production (input) and removal
(output) of ROS (Fig. 5; Moison et al. 1995). The input of *O normally consists of production by
mitochondrial and eicosanoid metabolism and by xanine oxidase after ischemia/reperfusion (Ben:jer
et al. 1994). Activated neutrophils also produce *O, which disrnutates to HO. Most of the HO is
converted to HOCIby myebperoxidase (Gutteridge et al. 1989). The most reactive oxygen metabolite,
"OH, is produced by decomposition of HO in the presence of non-protein-bound transition metals
suchas Fe(I). However, non-protein-bound ferrous iron normally does not occur (expect in cases
of oral ferrous salt therapy) since iron is maintained in the oxidized form by ceruloplasmin and
rigorouslybound to transferrin andferitin (Gutterridge and Quinlan 1993). These proteins are referred
to as primary antbxidants, since theyprevent the production of ROS.
mitochondria ..: HOCI
eico.scznoid metabolism leukcytilil. NO
O=*O2 H20=" OH
ceru|oplasmin transferrin ferritin
xanthine oxid.ase Input
glutatho.ne rflow [ p,mtein .oxidation
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cmtioxldant enzymes (znfioxidant sulbstances
superoxi.de dismutczse vitamin C and E
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g|,utathione recycling biiiliirubin
glu/athione reductase * sulfhydryl groups
Figure 5" Theinput modelofROSshov factors which increase anddefend oxidative stress
andwhatresults in an overflowsituation. Moison et aL (1995).
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"NO is produced as an intercellular messenger by endothelium and neurons and plays important roles
in vasoregulation and syntic plasticity. Activated macrophages and neutrophils also produce "NO in
simiar rates as O2, and therefore the "NO can be converted intoONOO (Beckmann et al. 1994).
The output of ROS depends on secondary antbxidants, consisting of antbxidant enzymes and
antbxidant substances (Gutteridge et al. 1989). Superoxide dismutase converts *O2 into HO2, which in
turn is reduced to water by catalase and glutathione peroxidase. The latter enzyme requires glutathione
(GSH) as a substrate, which is oxidized to GSSGdurhg H20 catabolism. Glutathione reductase reduces
GSSGbackto GSH, which in itself can scavenge "O_ and "OH (Doelman et al. 1990). Other antbxidants
such as vitamh C, vitamin E, uric acid, bilirubin, and protein sulfhydryl groups inactivate ROS (Halliwell
et. al. 1990).
An increased production or decreased removal of ROS, i.e., an imbalance between input and
output, results in oxidative damage of lipids, proteins and DNA. This leads to lipid peroxidation and
membrane disnJption, enzyme inactivation and sulfhydryl oxidation and DNA strand breakage. These
processes result in celltoxicity, orgm malfunction, and eventuallyin disease (Frank 992).
DNA strand breakage wasobserved by Akasaka (1995) who found that Fe
2/ resulted in increased
formation of 8-hydroxydeoxyguanosine in pZ189 DNA from Escherichia coli and increased supF
mutations (up to 50%). This effect could be suppressed by catalase and SOD which is in agreement
with the menlJoned defense systems (see figure 4).
none 40
Fe:+ (75.M) 20
Fe2+ (125M) 0
8-OHdG per 10 dG
+catalase (20 units/ml)
+catalase (200 units/ml)
+SOD (20 unlts/ml)
50.g of plasmid pZ189 was incubated in 0,1 M potassium phosphate buffer
(pH 7.4) with different concentrations of Fe2/ at 37"C for 30 m|n.
Figure 6" Induction of 8-Hydroxyguanosine formation byFe
/ andtheeffects ofcatalase and
superoxidedisntase (SOD). Akasaka et aL (1995).
Henle et al. (1996) and Luo et al. (1996) investigated the iron-mediated Fentons reaction under aerobic
and anaerobic conditions to the deoxyguanosine and deoxycytidhe famiies respectively. Due to the
oxidative damage 20 degradation products of deoxyguanosine and 26 of deoxycytidine were found
with the help of the HPLC technic. There was no difference in reactions between Fe(I) and Fe(ll)
spedes if the Fe(ll) spedes could be reduced by NADH.
These results show that due to iron(ll) oxidation "OH radicals cause serbus damages to DNA
constituents, and that the reduction potential is a good parameter for the characterization of iron(Ill)
compounds.
5. Preclinical and Clinical
5.1 Lipid peroxidation
Marx et al. (1996) compiled a list of clinical conditions including more than 60 toxic states where
reactive oxygen radicals are thought to be involved.
One of the most observed damages is lipid peroxidation. Fuhrman et al. (1 994) showed that
hydroxyl radical, but not superoxides or hydgenperoxides, mediated the iron induced cellular lipid
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peroxidation. This means that SOD and catalase had no protective effect in case of J-774
macrophages, but also (and most important)that "OH radicals and notO radicals or HO are
involved in lipid peroxidation (see figure 2).
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Figure 7" Involvementof free radbals in iron-induced cellularlipidperoxidation in J-774 macrophages
Fuhtrnann et al. (1994).
5.1.1 In Pregnancy
It has been reported that in uncomplicated pregnancy there is an increase of
lipoperoxidationproducts in serum as gestation progresses (Hubel 989). This finding correlates with
changes in lipoperoxidative activity of the placenta (Cester 1994) and with an increase of total serum
lipids. Controversial data is avalable on the antbxidant capacity in pregnancy. Stak et al. (1993)
reported that lipid peroxidation is controlled by an adequate antbxidative response dumg normal
pregnancy.
Wisdom et al. (1 991) reported in PIH (Pregnancy induced hypertension) a decrease in plasma thiols
andSODand an increase in ceruloplasmin level, suggesting increased free radical activity. Whether this
situation is a cause or an effect of oxidative stress in PIH has notyet been eluddated.
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Plasma concentration of various antioxidants were significantly lower
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Figure 8" Plasma concentratbn of antbxidants in patients with ecla’npsia and the control group.
Jendryczko e al. (1995).
142P. Geisser Metal-BasedDrugs
Jendryczko et al. (1995) found that the total radical trapping capacity of the antbxidants in plasma
(TRAP) in patients with eclampsia, was lower than in the control group. Figure 8 shows a marked
difference in sulfides and disulfidesconcentratbns in comparison to the controls.
These findings suggest thatoxygen free radical toxicity occurs in patients with eclarnpsia. The excess
of free radicals mayin turn be a factor that contributes to the complication of eclarnpsia. Davidge et al.
(1 992) reported sim|ar results and showed thatthe antbxidant activity increases durhg gestation.
Antioxidant 100
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8O
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0-13 14-26 2732 33-40 iLabor PP
PP=postpartum
n=43
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Figure 9" Antbxidantactivity in an uncomplicatedpregnantpopulation. Davidge et al. (1992).
5.1.2 In Prernatures and Children
In premature infants oxygen free radical mediated tissue injury is impicated as a major factor
in the pathogenesis of observed long term complications. Inder et al. (1994) observed a relationship
between lipid peroxidation, antbxidatbn activity, and outcome in cases of verylowbirthweight infants.
*p<O,O 80 control
"*p<0,01
vs. control
MDA+TBA, vitamin E, and glutath|one peroxidase in the
cord blood of full term and premature |nfonts who
subsequently did or did not develop chronic lung disease
Premature infants:
II
Chronic lung
disease absent
(n=6)
n
Chronic lung
disease present
(n=!6)
Figure 1 O" Lipid peroxidation as a measure of oxygen free radical dama2e in very low birthweight
infants. The results were obtned from the cord blood of full termandpremature infants. Inder et aL
(1994).
Khaled eta. (1995) studied the influence of protein supply to malnourished children and found a
decrease in oxidative stress parameters and an increase in RBP (reUnol binding proteiq), prealbumin
and albumin.
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age (month): 34+_8 Pre (n=8) Post (n=8)
At day before starting of dietary supplementofion After 21 days of dietary supplementation
Figure 1 1" Biochemical parameters of malnourished children before
supploment,ion. Khalod et aL (199).
and after dietary
In cases of iron deficiency in children, high levels of polyunsaturated fatty acids in erythrocytes
membranes and an increased concentratbn of lipid peroxide (LPO) products (MDA and diene
conjugates) in plasma and eryth rocytes have been reported (Soboleva et al. 1994).
Exactly in these situations with increased oxidative stress iron therapy is often
required, but only the use of iron preparations without a further increase of
oxidative stress will be adequate.
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MDA in plasma MDA in erythrocytes
Figure 12" Content ofLPO products in plasma and erythrocytes in iron defbient in children (LID
latent iron deficiency, IDA iron defbiencyanea). Soboleva et al. (1994).
5.2 Toxicity
The toxicity of iron is explained by its abiity to catalyze the formation of oxyradicals with
resulting lipid peroxidation. Because of the high concentratbn of polyunsaturated fatty acids in their
membranes, mitochondria appear parcularly susceptible to peroxidation (Danielson et al. 1996,
Geisser et al., 1992, Zimrnrman n 1988).
Hiraishi et al. (1993)found thatonly Fe+ e.g. produced by reduction of cellular Fe+ appears to be a
prerequisite forthemediation of damage in gastric epithelium. This reduction is independent of
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extracellular "O2 or cellular xanthine oxidase-derived "O2. Further, the reaction of H202 with Fe2+,
presumablyforms a more reactive peroxo complex, which may yield "OH or higher oxidation states of
iron (Halliwell 1982; Sutton et al. 1989), leads ulti’natelyto celldamage.
These results strongly reflect the findings of Schaub et al. (1984) and Juji(1976). They found serious
gastric ulcers and erosions after the appication of ferrous sulfate to rabbits at a dosage of 230 mg
Fe/kg body weight. With iron polymaltose complex at the same dosage no visible changes could be
observed.
After administration of Iron
Polymaltose Complex (IPC Maltofer)=
No visible changes.
After administration
of non.encapsulated
Fe(ll)-sulphate: Serious gastric ulcers
and erosion of fuher areas.
Figure 13" Stomachs of animals after admhistra#on of FeSO, and IPC (iron polyrnaltose complex).
Schaub et al. (1984).
Kadiska et al. (1 995) investigated the formation of hydroxyl radicals by electron spin resonance (ESR)
spectroscopy in rats with chronic dietary iron loading, using fenic citrate. The results show that ferric
citrate leads to radical generation in the bile. Thisis in correlationwiththe redox potential of ferric
citrate (+ 600 mV)(figure 3).
Peroxidatlon
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at pH 7,4 1,6
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0,8
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(molar ratio)
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!Ferrous ammo-
nium sulphate
Ferrous ascorbate
I :20)
Ferric citrate
A B C D E F G
Figure 14" Peroxidation of rabbit smal intestinal microvillus membrane vesicles by varbus iron
compounds. Fodoret al. (1988).
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Fukuda et al. (1 996) found that Fe(ll)-NTAinduces acute renal proximal tubular necrosis in rats,
a consequence of free radical-mediated oxidative tissue damage. A single intraperitoneal Fe(II)-NTA
treatment (15 mg Fe/kg bodyweight) induced a production of MDA and the loss of sulfhydryl contents
in the kidneys, resulting in a30% reduction of glutathione S-transferases (GSTs).
Fodoret al.(1988) found thatferus iron in acombination of 1:1 and 1:20 with ascorbic acid gives
a high increase of MDA production at pH 7.4 in rabbits sinai intestinal microvillesmembrane vesicles.
Naito et al. (1995) developed a new gastric ulcer model and found that ascorbic acid in
combination with Fe =+ produced significantly more ulcers than ascorbic acid or Fe* alone.
The fact of severe intoxication of young children shows that toxicity of ferrous salts is a real clinical
problem as pubished by the FDA 1994.
The number of young children who have accidentally swalowed iron has more than doubled since
986. Since 986, reports of more than 110 000 children under 6 who accidentally swalowed iron
tablets were made to poison control centers. Many of the chiUren were hospitalized, and at least 33
died.
5.3 ROS, Iron status/therapy and immunology
it is very interesting to note that ROS, iron status, and iron therapy influence
immunological paramaters. The reactive oxygen spedes (ROS) have a central and important role
in the activation of the transcriptbn factor NF-B, which is built up by two subunits p50 and p65 and
held together by IB. Different pathogenicand pro-inflarnrnatoricstirnuli, such as HO, different noxes
(UV-irradiation, xenobioticaforexanle ferrous salts), T-cell mitogens, cytokines, and the infection with
bacteria and viruses lead to a rapid activation of NF-B. All of them lead to a production of
ROS. As a result NF-B is liberated,absorbed bythe cell nucleus and bound to the DNA-sequences
of the target genes. Such target genes are immune relevant genes, which code for cytokines, immune
receptors, adhesion molecules and acute phase proteins. Viruses like HIV-1 use also NF-B as a ,,host
celt’ forthe repication of the virus genom (Blum 996). This mechanism also explains the rapid increase
of ferrith (acUve phase protein) after iron(ll)-salt therapy. As show below, a ferritin increase does not
always reflect an increase of depot iron (please see chapter 6).
T-cell Mitogens
Noxes: UV-light, Xenoblotica CytoSines
Granulocyts \, , ++ |nfection With Bacterio Viri
H202+
Membrane
ROS
Kinose
Proteae
Cytokines .++++++++++i++++++++X."’"++:":+++
+ +++":+++’
Virus Replication
Immune Receplors Acute +Phase Proteins
AdKesion .Molecules
Figure 15:/:POSp/ays a central role in the activation ofNF-+B (Explanation see text) B/um(1996).
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Due to iron deficiency, the folbwing immunological parameterswitlchange (Santos et al. 1990)
CD3 CD3 CD4 CD4 CD8 CD8 CD4
% x0’/I % xo’/I % xOVI
o o o
Controls (n:21) Iron deficiency (n=21)
(n=Number of subjects,) * p = values<0,01
Figure 16" Partial immunological profile of patients with IDA (iron deficiency anerda). Santos et al.
(1990).
The effects of iron therapy on the different immunological parameters have to be carefully interpreted.
Thisis because on theone hand, absolute and relative values can not always be compared, and on the
other hand different iron preparations seem to have different effects. There is also an inlJence of
concomitantdiseases and the initial iron status before starting anytherapy, e.g. the patients of Thibault
et al. (1993)have not shown any effect on the iron parameters durhg therapy, so no effect on
immunological parameterscan be expected.
Zanni et al. (1989) found an increase of CD8
/ and a decrease of CD4
/ cells using iron(lll)-protein
sucdnate for iron deficiency therapy. That means that after norrralizatbn of the hematologica:
parameters the immunological situation is stil bad. This is because iron(lll)-protein sucdnate can be
reduced by physiological redox systems (cf. figure 3) to Fe(I)-spedes and as a result "OH radicals can be
produced, thus havhg a negative effect on CD4 cells.
Djeha et al. (1992) found that Fe(II)-NTA caused a decrease in the CD4/CD8 ratb, mainly due to the
depression of the proportion of CD4
/ cells and a more modest increase in the proportion of CD8
/ cells.
Since proliferatbn wasalso reduced underthese conditions, the results may reflect a selective toxic or
antip roliferative effect on the CD4 subset.
It is interesting to note that the iron compounds, havhg an inhbitory effect on the prolferative
properties, also have a reduction potential which allows a reduction by "O or NAD(P) H,
generating Fe* and as a result "OH radicals.
5.4 Erythropoietin (EPO) activity and ROS
Said et al. (1995) showed that both Fenton and xanthine plus xanthine oxidase caused a
significant reduction of EPO activity in mice. The treatment of EPO with HO alone resulted in a
relativelyslight reduction of the activity.
The addtion of chelating agents does not prevent the interaction with EPO as they only build stable
complexes with Fe(ll)- but notwith Fe(I)-spedes.
As a result of these findings, iron preparations which induce the Fentons reaction should not be
combined with EPO.
There is also some evidence that enzymatic antbxidant systems, represented by SOD and GPx, are
decreased in erythrocytes of haernodialysis patients (Zirna et al. 1996). In such situations iron(ll)-salt
therapy should be avoicled.
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Delmas-Beauvieux et al. (1995) fourd an increase of SOD, GPx and Cat in the erythrocytes in
haerrodialysed patients treaed with EPO together with iron (in form of parenteral iron polymaltose
complex) compared to single EPO or iron treatment. These results indicate the particular role of this
therapeuticassociation in the induc;tion of enzymatic defense viathe increased rejuvenation of RBC.
The findings are in agreement witch the reduction potential of iron polymaltose complex, which shows
thatno iron(ll),species, and as a rsult of this, no "OH radicals areformed (figure 3).
6. Effects of special Iron Complexes
Ciufli et al, (1991 measured ;,,in vivo" lipid peroxidation induction by different iron complexes in the brah
cortex of rats. In the presence of 1 mM solution of ascorbic acid, the generation of MDA
(Malondialdehyd) was ’similar for iron polymaltose, iron sucrose and ferritin.
None Iron-saccharate
’ t" *"* p0,001
I- **" p0,01
Iron chloride Iron-polymaltosate
Ircn-EDTA Ferritin
Extent of peroxidation (MDA nmol/mg protein)
Figure 1 7: Iron(lll)-oc)mplex-induced lipid peroxidation in rat brah cortex homogenate Ciuffi et al.
(1991).
Thisis in agreement with the measured redox potentials of these compounds (see figure 3). It was also
shown that DL-(x-tooopherol, methylprednisolone and D-penicilarnine significantly decreased the iron
induced lipid peroxidation, whereas desferrioxamine was not effective. This can be explained by the
high stability of the investigated iron complexes (Geisser et al. 1992).
S
A 3,3
Serum ferriti" i RSC fert,;a
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B
27,4
Ferrous Sulphate
Ferric iron Complex
Placebo
n:l 5 m.en per group
Figure 18" Changes in iron status in iron depleted male subjects after 6 months iron therapy with
FeSO, ironpolymaltose complexandplaeebo Salonen et al. (1996).
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Salonen et al. (1996) cared out a 6-month double bli,nd trial evaluating the effects of iron
supplementation in men with Iowiron stores with eitherferBu,s sulfate or iron polymaltose complex. The
susceptibiity of verylowand Iowdensity lipoproteins to oxiction increased in the ferrous sulfate group
by 8.8% (P< 0.05) compared to the placebo group and by 12.8% (p< 0.05) compared to the iron
polymaltose complex group. Theamount of lipid peroxida’,tion product increased due to ferBus sulfate
by 13.8% (p< 0.05)compared to the iron polymaltose ,complex, with a more accentuated increase in
hemoglobin levels in the iron polymaltose group (figure 18,19)
(Utiization studies using the twin isotope technic haveshown that iron fromiron polymaltose complex is
equally utiized in humans and anirrs as fromiron(ll}-salts (Jaoobs 1979, 1979, 1984)).
Maximal
oxidation rate
Copper induction
A
0,79
Lagtime to oxidation
Ferrous Sulpihate
Fe...c Iron Complex
Placebo
n=15 men per group
Figure 19" Changes in oxidation susptibiity in iron depleted male subjects after 6 months iron
therapy withFeSO, ironpolymaltose complexandplaoebo Salonen et aL (1996).
These results showthe role of rapidly absorbed and distributed ionic iron in oxidation susceptibiity of
lipoproteins in humans, and are in correlation with the redox potential of iron polymaltose as well as with
the fact that Fe
/ induces oxidative stress. The findings have important impications rega’ding the
treatment of irondeficiencyanerria. They indicate that a rapid correction of iron stems by
supplementation with ferrous sulfate, at least in combination with ascorbate, may
have undesirable health effects and suggest that if iron supplementation is
necessary, non-ionic iron polymaltose products are preferable to ferrous sulfate.
It hasto be mentioned thata ferdtin incase doesnotalways reflect an incase in depot iron. Cain) et
al. (1995) have presented datawhid’ suggest that, under conditionsof oxidative stress, liverferdtin can
act either as a pro-or an anti-oxidant in a time-dependent manner. In fact its early degdation
contributesto the expansion of the intBcellularfree iron pool that, later on, activates multiple molecular
mechanismsto reconstitute ferdtin content, thuslimiting thepro)xidantchalenge of iron. It is obvbus
thatirontheBpy doesinc,ase the free iron pooL In case of iron therapy with iron(ll)-salts or
with hem iron, not only is the free iron pool increase.d, but also the oxidative stress
by the reaction of Fe+with oxygen. As a result, a ferdtin increase can be observed
without a correlation with the amount of depot iron (see figure 44 Fig 44).
7. Conclusion
Physicochemical data show that molecular oxygen develops a high reactivity especially in
combination with trace elements forexarrple Fe, Mn etc. by catalization of different biobgical oxidation
processes. Thereby ROS (Reactive oxygen spedes) are produced, which can react with all kind of
molecules yielding in the formation of denaturation products which can be toxic. It is shown that an
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input/output model is suitable to explain how much ROS are produced and detoxified in a so called
steady state situation, and what kind of reactions willoccur in case of overflow. The concept of reduction
potentials for all types of redox processes involved leads to a clear and helpful instrument for the
explanation and forecasting of such reactions.
Clinical data show that the so-called oxygen toxicity is unlkely to cause a number of pathological
phenomena, unless the human (oranirnal) organism is burdened with excess unphysiololical iron.
Except forcases of genetic deficiency, oxygen toxicity appears to be man-made.
The most frequent observed damage is lipid peroxidation, which for example is found in cell
membranes,fibroblastand macrophages, in pregnancy and prematures, in malnourished children and
in children with IDA (iron deficiency anemia), it is a well documented fact that ferrous salts and fenic
complexes with a reduction potential higher than that of NAD(P)H/NAD(P) lead to a great variety of
undesirable effects in livhg organism: forexample inference with ROS steady state and immunological
parameters, toxic manfestatbns on kidney and bile, neu3toxic/neurodegenerative diseases, and DNA
damages.
Undoubtfully there is a coincidence of status related oxidative stress for example in pregnancy,
prematu rity, IDA and the need of high iron supply. That means that the oxidative stress situation can be
worsened by iron therapy, especially when the reduction potential is not considered. Iron overload,
especially acute iron overload, increases oxidative stress parameters too. It is also a fact that ascorbic
acid can develop a pro-oxidative effect in combination with iron. This leads to the recommendation that
therapeutically used iron preparations should not be combined with ascorbic acid.
There is evidence that iron complexes of type and II (for classification see Geisser et al. 1992), for
example iron dextran, iron dextrin (iron polymaltose)and iron sucrose, do not provoke an increase of
ROS production in living organisms. These complexes have very simlar properties to feritin and are
therefore non-toxic.
Type Characteristic Toxicity* Reduction Preparations
potential
Oral Intravenous
Type robust and strong > 2500 >2500 < 324mV Iron Dextran BP/USP
Iron Dextrin injectable
Typell half robust and >2500 > 200 <-324mV
medium strong
Iron sucrose complex
Iron polymaltose
complex
Type III lable and weak 429-1000 13-16.5 > -324mV
LDo white mice in mg Fe/kg bodyweight
Iro n(lll)-gluconate
Iron(lll)-dtrate
Iron(lll)-so rbitol
Nevertheless for iron supplementation the most widely used form is ferrous sulfate as mentioned by
Hider (1996) on the fifth international conference on disorders of iron metabolism. Although the
bioavailablity of Fe(I) (ferrous) salts is generally acceptable, many patients suffer side effects, resulting
in poor compliance. Metal ions, including Fe(I), tend to induce an emelJc effect which can be
ame|orated by chelation. In most cases however, chelation reduces the absorption of the metal from
the gut. An additional potential hazard with relatively high doses of Fe(I) salts is that they generate
damaging hydroxyl radicals in the presence of vitamin C and oxygen. Unfortunately, the bioavailablity of
Fe(lll) salts is generally much lower than that of the corresponding Fe(I) compounds, and
consequently ferric salts are notwidely usedforsupplementation purposes. Recently, however, two
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new Fe(lll) preparations have been developed that possess acceptable bioavailabiities, namely
iron polymaltose and iron maltol. These preparations may offer real advantages over ferrous
sulfate, especiallyforthose patients, who experience unpleasant side effects with iron(ll) preparations
(Hider 1996).
To avoid an increase of oxidative stress dung iron theBpy the folbwing recommendations should be
folbwed:
No use of iron(ll)-salts for’therapy of irondeficiency and iron ’Supplementation.
No use of ascorbic acid in combination with iron(ll)-salts.
No use of iron(lll)-compounds and complexes with reduction potentials higher than
324 mV at pH 7.
Use of only iron(lll)-complexes with reduction potentials lower than -324 mV at pH 7
and with a similar substructure as ferdtin.
Recommended compounds:
iron de xtran
iron dextrin (iron polymaltose)
iron sucrose (saccharated iron oxide)
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